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abstract: Variation in the Storkhead box-1 (STOX1) gene has previously been associated with pre-eclampsia. In this study, we
assess candidate single nucleotide polymorphisms (SNPs) in STOX1 in an independent population cohort of pre-eclamptic (n ¼
1.139) and non-pre-eclamptic (n ¼ 2.269) women (the HUNT2 study). We also compare gene expression levels of STOX1 and
its paralogue, Storkhead box-2 (STOX2) in decidual tissue from pregnancies complicated by pre-eclampsia and/or fetal growth
restriction (FGR) (n ¼ 40) to expression levels in decidual tissue from uncomplicated pregnancies (n ¼ 59). We cannot conﬁrm
association of the candidate SNPs to pre-eclampsia (P . 0.05). For STOX1, no differential gene expression was observed in any
o ft h ec a s eg r o u p s ,w h e r e a sSTOX2 showed signiﬁcantly lower expression in deciduas from pregnancies complicated by both
pre-eclampsia and FGR as compared with controls (P ¼ 0.01). We further report a strong correlation between transcriptional
alterations reported previously in choriocarcinoma cells over expressing STOX1A and alterations observed in decidual tissue of
pre-eclamptic women with FGR.
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Introduction
Pre-eclampsia is a serious complication of pregnancy and a major
cause of preterm intervention by Caesarean section, as delivery
relieves symptoms. The condition presents with de novo elevated
blood pressure and proteinuria after 20 weeks of pregnancy. Severe
pre-eclampsia is not well deﬁned, but assessment for severity includes
both the mother (severe hypertension, end organ manifestations and
preterm disease), and the fetus (intrauterine growth restriction, fetal
movement assessment and oligohydramnios) (Gifford et al., 2000).
As deﬁned in clinical practice,  20% of pre-eclamptic cases are
severe. Early identiﬁcation, as well as more reﬁned treatment
options, is particularly important for these women, and this remains
a major challenge in obstetric medicine. Thus, there is a rationale
for concentrating research efforts on severe cases (Gifford et al.,
2000).
Pre-eclampsia is a complex disorder, including both placental and
maternal components. Disease heritability is as high as 54% (Salonen
et al., 2000), but a distinct pattern of inheritance is not known.
Whole genome linkage studies of families with an increased preva-
lence of pre-eclampsia have identiﬁed several genetic susceptibility
loci for pre-eclampsia (Harrison et al., 1997; Arngrimsson et al.,
1999; Moses et al., 2000, 2006; Lachmeijer et al., 2001; Laivuori
et al., 2003; Johnson et al., 2007). Several studies have suggested
the involvement of epigenetic mechanisms for the disease (Graves,
1998), and evidence for a maternal effect in one of the pre-
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on chromosome 10q22 (Oudejans et al., 2004). The exons of 17
positional candidate genes in this region were sequenced in a
Dutch cohort of families with two or more sibling pairs
affected by pre-eclampsia (van Dijk et al., 2005). All families with
increased prevalence of pre-eclampsia showed missense mutations
within the Storkhead box-1 (STOX1, AK057891) gene on chromo-
some 10q22, identical between affected sisters (van Dijk et al.,
2005).
The STOX1 gene encodes a winged-helix domain-containing tran-
scription factor, and is believed to play a role in the differentiation
of trophoblast cells (van Dijk et al., 2005). The longest isoform of
the STOX1 protein, STOX1A (NM_152709) exerts regulatory
effects in several tissues (van Dijk et al., 2010a). Over expression
of STOX1A in choriocarcinoma cells (JEG-3 cell line) was shown
to be associated with transcriptional alterations similar to those
observed in third-trimester pre-eclamptic placentas (Rigourd
et al., 2008). The predominant variation co-segregating with pre-
eclampsia disease status in the Dutch families (van Dijk et al.,
2005), STOX1A-Y153H (rs1341667) is located in the DNA
binding domain. Recently published data suggest that this variant
may negatively regulate trophoblast invasion by up-regulation of
the cell–cell adhesion protein a-T-catenin (CTNNA3) (van Dijk
et al., 2010b).
Storkhead box 2 (STOX2, AB037813) has been identiﬁed as the
only known human paralogue to STOX1 (van Dijk et al., 2005;
Kivinen et al., 2007), but to our knowledge little is known of its func-
tion. In humans, there is evidence that STOX2 is a component of a
molecular proﬁle unique and globally characteristic of uncommitted
stem cells (Thomas et al., 2008). The STOX2 transcript is also included
in a transcriptional proﬁle observed with increased inﬂammatory
response to air pollutants, differing between pregnant and non-
pregnant mice (Fedulov et al., 2008). The gene is situated at chromo-
some 4q35, near a replicated region of known, suggestive linkage to
pre-eclampsia on chromosome 4q31-q32 (Harrison et al., 1997;
Moses et al., 2000; Laivuori et al., 2003).
The involvement of STOX1 in pre-eclampsia observed in the Dutch
families (Oudejans et al., 2004; van Dijk et al., 2005) has not been con-
ﬁrmed in independent studies (Berends et al., 2007; Kivinen et al.,
2007; Iglesias-Platas et al., 2007). It has therefore been hypothesized
that STOX1 is relevant to a clinically severe subgroup of women
with early onset of the disease, and fetal growth restriction (FGR)
(Oudejans et al., 2007; Oudejans and van Dijk, 2008; van Dijk et al.,
2007).
In the present study, we investigated candidate functional single
nucleotide polymorphisms (SNPs) within STOX1 in an independent
large population-based pre-eclampsia cohort. The proposed
disease-causing STOX1A-Y153H (rs1341667) variant was tested
for association with deﬁned clinical subgroups of pre-eclamptic
women. We also compared decidual gene expression of STOX1
and STOX2 in uncomplicated pregnancies and pregnancies compli-
cated by pre-eclampsia, FGR or both. Furthermore, we compared
transcriptional alterations in Rigourd’s cultured trophoblast cells
with increased expression of STOX1A (Rigourd et al., 2008),
with transcriptional alterations seen in our clinically deﬁned
subgroups.
Materials and Methods
Candidate gene expression study
Human subjects
Women with pregnancies complicated by pre-eclampsia, FGR, pre-
eclampsia with FGR and women with uncomplicated pregnancies were
recruited at St Olavs Hospital, Trondheim, Norway and Haukeland Uni-
versity Hospital, Bergen, Norway from 2002 to 2006. Pre-eclampsia was
deﬁned as hypertension (blood pressure ≥140/90 mmHg) plus protei-
nuria (≥0.3 g/24 h or ≥1 + according to a dipstick test) on at least
two occasions, developing after 20 weeks of pregnancy (Gifford et al.,
2000). FGR was deﬁned by a stringent small for gestational age (SGA) deﬁ-
nition (birthweight ≤2 SD below the expected weight for gestational age
and sex, corresponding to the 2.5 percentile) (Marsal et al., 1996), con-
ﬁrmed by at least one of the following: reduced fundal height in serial
measurements, serial ultrasound biometry identifying failure to grow
along a consistent centile or abnormal umbilical artery wave form. Multiple
pregnancies and pregnancies with chromosomal aberrations, fetal and pla-
cental structural abnormalities or suspected perinatal infections were
excluded.
Decidual tissue collection
Decidua basalis tissue samples were collected by vacuum aspiration of the
placental bed during Caesarean section as previously described (Staff et al.,
1999; Harsem et al., 2004). Caesarean section in the control group was
done for reasons considered irrelevant to the study hypotheses (breech
presentation, cephalopelvic disproportion or maternal request). Samples
were ﬂushed with 500 ml sterile saline solution at room temperature to
remove excess blood. The decidual tissue was immediately submerged
in RNA-later (Ambion, Huntington, UK), incubated at 48C and stored
at 2808C for later RNA extraction. The quality of the decidual material
was assessed by immune histochemistry, as described in Eide et al.
(2006). Only specimens containing extravillous trophoblast (decidua
basalis) were included in the study.
Total RNA processing
Decidua basalis tissue was disrupted in a 2:1 (w/v) trizol:sample tissue mix
using a Polytron
w PT 1300 D digital, handheld homogenizer with a PT-DA
1307/2EC generator (Kinematica Inc., Lucerne, Switzerland). Total RNA
was isolated using a trizol extraction protocol with chloroform interphase
separation; isopropanol precipitation and ethanol wash steps. Isolated
total RNA was puriﬁed with an RNeasy Mini Kit using spin technology
(Qiagen, Valencia, CA, USA). Spectrophotometric determination of puri-
ﬁed total RNA yield (mg) was performed using the NanoDrop ND-1000
(Wilmington, DE, USA). Total RNA quality was measured using the total
RNA Nano Series II kit on the Agilent BioAnalyzer 2100 using the 2100
Expert software (Agilent Technologies, Germany). Synthesis, ampliﬁcation,
puriﬁcation and biotin labelled complementary RNA (cRNA) was pro-
duced from a total RNA template using the Illumina TotalPrep RNA
Ampliﬁcation Kit (Ambion, TX, USA), according to manufacturer’s instruc-
tions. Puriﬁed cRNA yield was determined spectrophotometrically using
the NanoDrop ND-1000.
A total of 1.5 mg puriﬁed cRNA per sample was hybridized onto Illumi-
na’s HumanWG-6 v2 Expression BeadChip
w following Illumina’s 6 × 2
BeadChip protocol (Illumina, San Diego, CA, USA). After hybridization,
the 6 × 2 expression arrays were washed, blocked, stained with
streptavidin-Cy3 (GE Healthcare, Buckinghamshire, UK) and dried prior
to them being scanned on the Illumina BeadArrayer 500GX reader
using Illumina BeadScan image data acquisition software (version
2.3.0.13). Illumina’s BeadStudio Gene Expression software module
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vidual sample and generate an output ﬁle for statistical analysis. The
control summary report generated by the Gene Expression software
module was used to evaluate the performance of the built-in controls
for each BeadChip. The control summary report summarizes signal inten-
sity, hybridization signal, background signal and the background to noise
level for all samples scanned in a particular batch.
Candidate gene association study
HUNT2 case/control subjects
The samples used for our candidate gene association study were retrospec-
tively identiﬁed from the second Nord-Trøndelag Health Study in Norway
(HUNT2). The HUNT2 study was conducted from 1995 to 1997. All resi-
dents above 19 years were invited and 75.5% of the invited women (n ¼
35.280) participated. This population is considered well suited for genetic
studies as it is homogeneous (,3% non-Caucasians) and stable (net out
migration of 0.3% each year). The HUNT2 survey included a questionnaire,
a clinical examination and collection of biological samples as previously
described (Holmen et al., 2003). Obstetrical data from these women were
obtained by linking the HUNT2 data with the The Medical Birth Registry of
Norway (MBRN). Physicians and midwives have been registering obstetrical
datafromalldeliveriesinNorwayafter16weeksofgestationinstandardques-
tionnairessince1967.Morethan1.8millionbirthsareincluded.Eachresident
in Norway is registered with an 11-digit personal identiﬁcation number, also
used for all national registries such as the MBRN and HUNT. The women
having experienced pre-eclampsia in one or more pregnancies, deﬁned as
newonsetofhypertension(bloodpressure≥140/90 mmHg)andproteinuria
(≥0.3 g/dor ≥1 + accordingtoadipsticktest),developingafter20weeksof
pregnancy (Gifford et al., 2000) were identiﬁed using diagnosis codes ICD-8
(before 1998) and ICD-10 (after 1998). Pre-eclamptic women with multiple
pregnancies were excluded. Two controls per case were identiﬁed at
randomamongparouswomenintheHUNT2cohortwithnoregisteredpre-
eclamptic pregnancy in the MBRN. All personal identiﬁcation numbers in the
total data set were randomly replaced by a serial number in order to ensure
patient anonymity.
Clinical characterization of the HUNT2 pre-eclampsia-cohort
Preterm delivery was deﬁned as delivery before 37.0 weeks (Gifford et al.,
2000), and FGR as delivery of a SGA infant (birthweight ≤2 SD below the
expected weight for gestational age and sex, corresponding to the 2.5 per-
centile) (Marsal et al., 1996). As fasting blood glucose was not available for
all the individuals in the study cohort, an International Diabetes Federation
(IDF)-proxy deﬁnition [waist circumference ≥80 cm plus any two of the
following: high-density lipoprotein (HDL) cholesterol ,1.29 mmol/l,
treatment for hypertension or blood pressure ≥130/85 mmHg, diabetes
diagnosed after the age of 30] (Hildrum et al., 2007) was used for assess-
ment of metabolic syndrome. This method has been evaluated in a cross-
sectional analysis of 10.206 participants in HUNT2 and no differences in
the prevalence of metabolic syndrome between fasting and non-fasting
groups were shown using the IDF-proxy deﬁnition (Hildrum et al., 2007).
Genotyping
DNA from pre-eclamptic (case) and non-pre-eclamptic (control) pregnan-
cies was extracted from peripheral blood leukocytes from blood clots or
from EDTA blood stored in the HUNT biobank, using the PURGENE
chemistry (Gentra Systems Inc, Minneapolis, MN, USA) for large
volumes or the MagAttract DNA Blood M48 kit (Qiagen, Hilden,
Germany) for low volumes (,400 ml) as previously described (Holmen
et al., 2003; Moses et al., 2007).
The four STOX1 missense SNPs described by van Dijk et al.( 2005) plus
two additional known STOX1 missense SNPs were selected for genotyping
in the HUNT2 case/control cohort. The additional STOX1 SNP was
selected from the NCBI SNP database (Homo sapiens NCBI Build 35;
dbSNP build 124). The six STOX1 SNPs were genotyped using Applied
Biosystems’ SNPlex
TM Genotyping System and sample genotypes were
interrogated using Applied Biosystems’ GeneMapper (version 4.0) soft-
ware as previously described (Moses et al., 2007; Roten et al., 2008).
Statistical analysis
Gene expression analysis
Decidual gene expression proﬁles were analysed using SOLAR (Almasy
and Blangero, 1998) as previously described (Goring et al., 2007). All
raw gene expression signals were initially log-transformed. To identify sig-
niﬁcantly expressed genes in decidua, the distribution of expression values
for a given gene across all samples was compared with the distribution of
the expression values of the control targets implemented in each
expression array. For each gene, we performed a x
2 tail test using a
false discovery rate (Hochberg and Benjamini, 1990) of 0.01 to determine
whether there was a signiﬁcant excess of samples with expression values
above the 95th percentile of the control null distribution (Goring et al.,
2007). The pre-processing of gene expression signals produces a sub-set
of signiﬁcantly expressed (detected) genes from the total number of
targets synthesized onto each expression array. Within each sample, the
mean log expression signal for each detected gene was ranked and
grouped into bin sets of 2.000 genes. Each bin set was then z-scored inde-
pendently. We applied a direct normalization procedure using an inverse
Gaussian transformation for each detected same gene across all
samples. This conservative procedure results in normalized expression
phenotypes that are comparable between individuals and across all
genes (Goring et al., 2007). To evaluate the magnitude of differential
gene expression between case (pre-eclampsia and/or FGR) and control
women, we measured the displacement of each detected gene’s mean
expression value between the two groups. We performed a standard
regression analysis on the case group to test whether the mean gene
expression level is signiﬁcantly different (up- or down-regulated) in the
case group compared with the control group.
When evaluating the correlation between transcriptional alterations
in Rigourd’s data set (Rigourd et al., 2008) and our data set
(E-TABM-682), we performed a Spearman rank test, as the beta-values
and the fold change values generated from these two studies are not
directly comparable.
The microarray data have been reported to ArrayExpress according to
MIAME standards with accession number E-TABM-682.
SNP association analysis
SNP association analyses of all selected SNPs were performed for the total
case/control cohort using Pearson’s x
2 statistic in the software package
SPSS 16.0 for Windows. The Y153H variation was analyzed separately
for subgroups of pre-eclamptic women and control women (FGR, recur-
rence) for both a dominant (CC + CT genotype frequency versus TT gen-
otype frequency) and additive (C allele frequency versus T allele
frequency) genetic model. Multivariate logistic regression was used to
model pre-eclampsia as the (dichotomous) dependent variable against
maternal age. Odds ratios (OR) with 95% conﬁdence intervals were calcu-
lated. Concordance with Hardy–Weinberg proportions was tested using a
x
2 goodness-of-ﬁt statistic. A threshold of a ¼ 0.05 was set for statistical
signiﬁcance of all computed analyses.
Clinical characterization
Descriptive statistics means and standard deviations were computed in the
software package SPSS 16.0 for Windows. P-values were computed based
on t-test statistics. Recurrent and non-recurrent pre-eclamptic cases were
962 Fenstad et al.analyzed separately. Each pre-eclamptic group (recurrent and non-
recurrent) was compared with the non-pre-eclamptic group. Multivariate
logistic regression was used to model pre-eclampsia as the (dichotomous)
dependent variable against maternal age. A threshold of a ¼ 0.05 was set
for statistical signiﬁcance of all computed analyses.
Ethical approval
Informed written consent was obtained from all participants in this study.
The study was approved by the Regional Committees for Medical
Research Ethics, the National Data Inspectorate and The Directorate of
Health and Social Welfare, Norway. Ethical approval for genotyping the
Norwegian case/control cohort (HUNT2), decidual RNA processing
and statistical analysis of decidual RNA was obtained from The University
of Texas Health Science Center at San Antonio, Institutional Review
Board.
Results
Decidual tissue candidate gene expression
analysis
Decidua basalis tissue was vacuum aspirated from the placental bed of
14 women with pre-eclampsia, 9 non-pre-eclamptic women with FGR
neonates, 29 women with both pre-clampsia and FGR
(pre-eclampsia + FGR) and 59 normal pregnancies. Seven samples
of low RNA quality were excluded (assessed by the RIN value and
visual evaluation of digital electrophoretic gel pictures). We therefore
processed a total of 104 samples. Clinical characteristics of the study
groups are presented in Table I.
Both the STOX1 (NM_152709.3) and STOX2 (NM_020225.1)
targets were represented on each expression array as a single
known transcript, respectively and were annotated from NCBI’s
Human Genome Build 36.2, RefSeq content release 17. The
expression of both the STOX1 and STOX2 targets were signiﬁcantly
detected in decidual tissue using a conservative false detection rate
of 1%. To evaluate the magnitude of differential gene expression,
we measured the displacement of the mean STOX1 or STOX2
expression signals in the case group from the control group. We per-
formed this measurement on the three different sample groups and
found no signiﬁcant difference in STOX1 gene expression levels (P .
0.05) (Table II). The expression of STOX2 however, was signiﬁcantly
lower in the group of pre-eclamptic women delivering FGR neonates
compared with the control group (P ¼ 0.01) (Table II).
In the study by Rigourd et al. (2008), 259 of the 500 most up/
down-regulated genes in pre-eclamptic placentas had detectable tran-
script levels in the microarray experiment comparing JEG-3 cells over
.............................................................................................................................................................................................
Table I Clinical characteristics of the cohort used in the gene expression analysis.
Pre-eclampsia (n 5 13) FGR
a (n 5 9) Pre-eclampsia with FGR (n 5 24) Controls (n 5 58)
Maternal age (years) 30+5* 34+43 1 +53 1 +5
Gestational age (weeks) 35+3** 32+5** 30+4** 39+1
Systolic blood pressure (mmHg) 153+18** 128+15 151+16** 116+11
Diastolic blood pressure (mmHg) 95+9** 74+89 7 +12* 70+9
Birthweight (g) 2364+510** 1225+21** 1118+470** 3619+469
Data are presented as mean+SD. All case groups were compared with controls and P-values were computed based on t-test statistics.
a≤2 SD of expected weight, conﬁrmed by at least one of the following: reduced fundal height in serial measurements, serial ultrasound biometry identifying failure to grow along a
consistent centile or abnormal umbilical artery wave form.
*P , 0.05; **P , 0.001.
...............................................
.................... .......................
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Table II Decidua basalis differential STOX1 and STOX2
expression analysis.
Sample group comparison Gene
STOX1 STOX2
b* P-value b* P-value
Pre-eclampsia versus control 0.39 0.19 0.07 0.81
FGR versus control 0.49 0.18 20.17 0.61
Pre-eclampsia with FGR
versus control
0.04 0.86 20.59 0.01
*The b (beta) value is the measure of displacement between the case and control group
mean expression signals and is expressed in standard deviation units. A positive b
implies a higher mean transcript expression signal in the case group compared with the
control group and is analogous to a gene/transcript being up-regulated. A negative b
implies a lower mean transcript expression signal in the case group compared with the
control group and is analogous to a gene/transcript being down-regulated. Values
signiﬁcant at the 1% level are outlined in bold.
........................................................................................
Table III Correlation between transcriptional
alterations seen in JEG-3 cells over expressing STOX1A
and alterations observed in decidua basalis tissue from
pre-eclamptic and/or FGR pregnancies.
Correlation coefﬁcient
2
(Spearman r)
P-value
Pre-eclampsia 0.16 0.004*
Pre-eclampsia with FGR
1 0.23 0.00008*
FGR 0.09 0.17
1≤2 SD of expected weight, conﬁrmed by at least one of the following: reduced fundal
height in serial measurements, serial ultrasound biometry identifying failure to grow
along a consistent centile or abnormal umbilical artery wave form.
2correlation between the degrees of up/down-regulation of 259 pre-eclampsia related
genes from the study of Rigourd et al. (comparing JEG-3 cells over expressing STOX1
with mock-transfected JEG-3 cells) with the present study (comparing decidua basalis
samples from patients with pre-eclampsia and/or FGR with control decidua basalis
samples).
*P , 0.01.
STOX genes and pre-eclampsia in decidua and HUNT2 963expressing STOX1A with mock-transfected JEG-3 cells. Of these 259
genes, 242 were found to have transcripts expressed above the back-
ground in the transcriptomic data from our material (E-TABM-682).
We observed a strong correlation (Spearman r ¼ 0.23, P ¼
0.00008) between the beta-values (ratio of up/down-regulation com-
pared with controls) for these genes in our subgroup of women
experiencing pre-eclampsia with FGR and the ratio of up/down-
regulation in the study by Rigourd et al. (2008). The beta-values for
the women with pre-eclampsia only, showed a weaker correlation
(Spearman r ¼ 0.16, P ¼ 0.004), and there was no correlation to
the beta-values for the non-pre-eclamptic women delivering FGR neo-
nates (Spearman r ¼ 0.09, P ¼ 0.17) (Table III).
The HUNT2 case/control cohort
DNA samples were available for 1139 women registered with pre-
eclamptic pregnancies (cases) and 2269 non-pre-eclamptic women
(controls) (Moses et al., 2007). Of the available cases, 1003 women
were registered with one and 136 women with more than one pre-
eclamptic pregnancy. Mean follow-up time from diagnosis in the
MBRN to inclusion in the present study was 25+10 years. As
expected, gestational age and birthweight differed between the
neonates in pre-eclamptic and non-pre-eclamptic pregnancies; the
pre-eclamptic women had a higher risk of delivering preterm, and of
delivering a FGR neonate (Table IV, P , 0.001). The metabolic syn-
drome, evaluated by data from the HUNT2 study, was also higher
in the case groups as compared with controls (Table IV, P , 0.001).
After adjusting for maternal age, the differences in clinical phenotype
between case and control groups remained signiﬁcant at a , 0.001
level (Table IV).
We also observed clinical differences between the recurrent and
non-recurrent pre-eclamptic groups (Table IV). The women in the
recurrent group delivered earlier (P ¼ 0.018) and the neonates had
a lower birthweight (adjusted for gestational age, P ¼ 0.055). The
prevalence of preterm birth was higher in the recurrent group
(22%) compared with the non-recurrent group (14%) (P , 0.01),
but the seemingly different prevalence of FGR (20 versus 15%) was
not statistically signiﬁcant (P ¼ 0.2). The P-values are adjusted for
maternal age. Metabolic syndrome at inclusion in the HUNT2 study
was more prevalent in the recurrent group compared with the non-
recurrent when adjusting for age at inclusion (P ¼ 0.019).
Statistical power analysis for the HUNT2 case/control cohort
A priori power calculations ad modum Lalouel and Rohrwasser (2002)
for the STOX1AY153H (rs1341667) variant demonstrated 90% power
to detect an effect size (OR) difference of 1.3 for the total case/
control (HUNT2) cohort and 1.9 for the recurrent pre-eclampsia
subgroup (n ¼ 136).
STOX1 genotyping and association analysis
The R18P STOX1 SNP failed the SNPlex assay design due to high hom-
ology and another two STOX1 SNPs were non-polymorphic. There
were no signiﬁcant differences in allele frequencies between the case
and control groups for the genotyped SNPs (Table V). There was a
high average sample genotype success rate of 87% (range 84–88%)
and all SNPs conformed to Hardy–Weinberg proportions (P . 0.05).
Assuming a dominant genetic model for the Y153H variant, it is
proposed that this variant becomes mutagenic through mechanisms
of imprinting either of STOX1 itself, or of downstream proteins (van
Dijk et al., 2005). Under this analysis model, the pre-eclampsia +
FGR subgroup did not show any association with the STOX1A-
Y153H variant when compared with the control group (Table VI).
However, the recurrent pre-eclampsia subgroup showed a tendency
towards higher incidence of the C-genotype (P ¼ 0.09) (Table VI).
Discussion
In this study, we demonstrate reduced decidual gene expression of
STOX2 in pre-eclamptic women delivering FGR neonates. To our
.............................................................................................................................................................................................
Table IV Clinical characteristics of the HUNT2 case/control cohort.
Pre-eclampsia
(recurrent
1, n 5 136)
Pre-eclampsia
(non-recurrent, n 5 1.003)
Control (n 5 2.269)
Maternal age at index pregnancy (years) 25+52 7 +6* 25+5
Gestational age (days) 271+20* 275+22* 282+18
Birthweight (g) 3.040+846* 3.238+837* 3.483+592
FGR
2 26 (20)* 147 (15)* 87 (4)
Preterm birth
3 29 (22)* 132 (14)* 114 (5)
Maternal age at inclusion in HUNT2 37+9* 40+11 40+11
Metabolic syndrome
4 30 (22)* 163 (16)* 212 (9)
Data presented as mean+SD or number (percentage). P-values are computed based on t-test statistics, each pre-eclamptic group is compared with the non-pre-eclamptic group. IDF,
the International Diabetes Federation; HDL, high-density lipoprotein; CI, conﬁdence interval.
1More than one pre-eclamptic pregnancy.
2≤2 SD of expected weight.
3Delivery before week 37.
4IDF-proxy deﬁnition; waist circumference ≥80 cm plus any two of the following: (HDL cholesterol ,1.29 mmol/l, treatment for hypertension or blood pressure ≥130/85 mmHg,
diabetes diagnosed after age of 30 or fasting plasma glucose ≥5.6 mmol/l) [43].
*P , 0.001.
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Rigourd et al. showing correlation between transcriptional alterations
of pre-eclamptic placentas (relative to controls) and JEG-3 cells over
expressing STOX1A (relative to mock-transfected JEG-3 cells)
(Rigourd et al., 2008). Transcriptional alterations in our decidua
basalis tissue (E-TABM-682) show the strongest correlation to
Rigourd’s data set in pre-eclamptic pregnancies complicated by FGR,
but not in non-pre-eclamptic pregnancies with FGR. Furthermore, in
a population- and registry-based cohort, we ﬁnd that women experi-
encing pre-eclampsia more than once are at a higher risk of compli-
cations and co-morbidity (preterm birth, lower birthweight and
development of metabolic syndrome) compared with those experien-
cing pre-eclampsia once. There is also a tendency towards higher
frequency of the C genotypes for the previously reported
STOX1A-Y153H variation (van Dijk et al., 2005) in this group of
women.
Reduced placental perfusion due to impairment of trophoblast inva-
sion and failed spiral artery remodelling are proposed to be pathogenic
features of both fetal growth restriction and pre-eclampsia (Brosens
et al., 1972, 1977). We believe the present study of decidua basalis
tissue, where these disease processes are taking place, to be an
important supplement to previous reports of STOX1 gene expression
in placental tissues (van Dijk et al., 2005; Iglesias-Platas et al., 2007;
Kivinen et al., 2007) and cultured trophoblast cells (van Dijk et al.,
2005, 2010; Rigourd et al., 2009). We show novel evidence that the
STOX2 gene is down-regulated in term decidua basalis from pre-
eclamptic women delivering FGR neonates. STOX2 resides on
chromosome 4q35, near a replicated region of suggestive linkage to
pre-eclampsia on chromosome 4q31-q32 (Harrison et al., 1997;
Moses et al., 2000; Laivuori et al., 2003). To our knowledge, the
role of STOX2 in the maternal–fetal interface is not known. Gene
duplication is an important evolutionary mechanism, and is a continu-
ous matter of research in evolutionary systems biology (Hughes, 2005;
Hittinger and Carroll, 2007). Studies of paralogous genes show that
duplication does not create genes with novel functions, but rather
daughter genes performing specialized sub functions of the ancestral
gene (Jensen, 1976; Conant and Wolfe, 2008). STOX2 has a high
sequence similarity to STOX1 (van Dijk et al., 2005; Kivinen et al.,
2007), and it is reasonable to hypothesize that it is involved in some
of the same biological processes. Therefore, the role of STOX2 in
.............................................................................................................................................................................................
Table V Genotyped SNPs within STOX1.
SNP Genotype (NN), Allele (N) Pre-eclampsia (proportion of total) Control (proportion of total) P-value
R18P Failed assay design
rs1341667 (Y153H) CC 412 (0.418) 840 (0.416) 0.9
CT 450 (0.456) 931 (0.462)
TT 124 (0.126) 245 (0.122)
C 1274 (0.646) 2611 (0.648)
T 698 (0.354) 1421 (0.352)
rs41278530 (L582F) Non-polymorphic
rs10509305 (E608D) AA 583 (0.591) 1206 (0.597) 0.5
AC 346 (0.351) 716 (0.355)
CC 57 (0.058) 97 (0.048)
A 1512 (0.767) 3128 (0.775)
C 460 (0.233) 910 (0.225)
rs41278532 (N825I) AA 953 (0.968) 1827 (0.972) 0.4
AT 28 (0.028) 50 (0.027)
TT 3 (0.004) 2 (0.001)
A 1934 (0.983) 3704 (0.986)
T 34 (0.017) 54 (0.014)
rs7904300 (A865T) Non-polymorphic
P-values were computed using Pearson’s x
2 statistic.
.............................................................................................................................................................................................
Table VI The STOX1A-Y153H variation in severe subgroups of pre-eclamptic women.
Y153H variation Pre-eclampsia 1 FGR
a Recurrent
b pre-eclampsia Control
Number of individuals genotyped 151 115 2010
Dominant model frequency CC + TC 0.881 0.930 0.878
OR* (CI) 1.0 (0.6–1.7) 1.9 (0.9–3.9)
P-value 0.92 0.09
aFGR, fetal growth restriction measured by birthweight below 2 SD for gestational age.
bMore than one pre-eclamptic pregnancy.
*OR for each of the subgroups of pre-eclamptic women compared with controls with 95% conﬁdence intervals (CIS) using x
2 statistics.
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eclampsia with FGR warrants further investigation. A comprehensive
assessment of genetic regulatory variation as well as a molecular func-
tional evaluation is required to conﬁrm the biological importance of
our observation.
Rigourd et al. recently showed a strong correlation between tran-
scriptional alterations in trophoblast cell-lines over expressing
STOX1A and transcriptional alterations shown in term pre-eclamptic
placentas (Rigourd et al., 2008). This supports the observation
made by others, that the possible disease-causing effects of STOX1
dysregulation are mediated through aberrant transcriptional regulation
of trophoblasts (van Dijk et al., 2005, 2010). The dysregulation of
STOX1 can potentially have deleterious effects as it affects the tran-
scription level of many other genes shown to be important in the
development of pre-eclampsia (such as Endoglidin, human Chorionic
Gonadotrophin, and Glial Cell Missing Homolog (Rigourd et al.,
2009). Furthermore, a direct effect of STOX1 on CTNNA3 expression
was recently conﬁrmed, affecting trophoblast differentiation and
growth (van Dijk et al., 2010b). When comparing the transcriptional
alterations of our deﬁned subgroups of women with the transcrip-
tional alterations in Rigourd’s trophoblast cell line over expressing
STOX1A, we conﬁrm their results from placental tissue in decidua
basalis. Furthermore, the observed correlation is strongest in the
group of women with both pre-eclampsia and FGR. Our ﬁndings
suggest that the STOX genes are associated with a severe fetal pheno-
type (FGR), interestingly though, only in pre-eclamptic patients, and
not in non-pre-eclamptic women delivering FGR neonates. This sup-
ports the opinion that FGR in pre-eclampsia and FGR alone represent
different pathogenic conditions, as discussed by others (Ness and
Sibai, 2006; Huppertz, 2008; Srinivas et al., 2009).
The analysis of gene expression in whole tissue harvested from
patients with manifest disease beneﬁts from describing the in vivo situ-
ation. However, interesting differences will potentially be masked due
to the heterogeneity of the material. Approximately 40% of cells in
decidua basalis are maternal leukocytes, 20% are extravillous tropho-
blast and 30% are decidual stromal cells (Benirschke et al., 2006). This
is a possible confounding factor; however, our results were inter-
preted in relation to, and are consistent with, earlier observations
(Rigourd et al., 2009; van Dijk et al., 2010b). Our ﬁndings are
limited to describing gene expression in decidua basalis samples col-
lected at birth; we do not report expression throughout the preg-
nancy. The strength of this study, however, is a thorough monitoring
by an obstetrician; multiple blood pressure and proteinuria measure-
ments, prenatal ultrasound measures and birthweight conﬁrmation,
providing a sound diagnostic basis (Eide et al., 2006).
There were no signiﬁcant differences in allele frequencies between
the case and control groups in the population-based cohort for the
genotyped candidate SNPs within STOX1. This is in agreement with
smaller population samples included in other studies (Berends et al.,
2007; Kivinen et al., 2007).
Severe pre-eclampsia is diagnosed by assessment of both maternal
and fetal phenotypes (Gifford et al., 2000). It has been shown that
mothers developing early onset pre-eclampsia have a higher preva-
lence of fetal growth restriction, as well as increased maternal morbid-
ity and cardiovascular risk later in life (Ness and Roberts, 1996;
Mostello et al., 2002; Brown et al., 2007). The MBRN did not
include information about onset of disease until 1998, and we are
therefore not able to include this parameter in our analyses. It has
been shown, however, that women developing severe pre-eclampsia
in the second trimester are at high risk of recurrent pre-eclampsia
as well as later life chronic hypertension and increased maternal mor-
bidity and mortality (Sibai et al., 1986, 1991; Odegard et al., 2000).
Therefore, research on multiparous pre-eclamptic women is encour-
aged as a tool of better understanding of disposition to, and develop-
ment of strategies for treatment and prevention of pre-eclampsia
(Gifford et al., 2000). Findings in our cohort are consistent with
earlier studies, as the recurrent group shows the highest risk of
preterm labour, of low fetal birthweight and the highest later life car-
diovascular risk, assessed as metabolic syndrome. We do ﬁnd a ten-
dency towards higher incidence of the C genotypes of the Y153H
mutation in the recurrent group under a dominant genetic model.
This ﬁnding is however, not signiﬁcant at the 5% level. Assessment
of the Y153H mutation in pre-eclamptic women delivering FGR neo-
nates did not show association. Thus, we cannot conﬁrm the hypoth-
esis that this variant is linked to severe pre-eclampsia, or
pre-eclampsia with FGR in the Norwegian population.
In the population-based part of the study, we are using registry data,
and some misclassiﬁcation can be expected. This will limit the power
to detect a true association. The prevalence and recurrence rates of
pre-eclampsia in MBRN are, however comparable to those reported
in other Nordic countries (Trogstad et al., 2001). Being born SGA
does not necessarily imply FGR, but can also reﬂect e.g. different eth-
nicity, constitutional smallness and chromosomal aberrations.
However, the growth curves used in this study are based on ultrasoni-
cally estimated fetal weights, appropriate for the population (which is
homogeneous) and considers the sex of the fetus (Marsal et al., 1996).
Furthermore, a stringent SGA deﬁnition of +2 SD is used, which is
more likely to identify the true FGR cases within the SGA group
(ACOG, 2002; Sheridan, 2005).This leads us to believe that SGA is
a good approximation to FGR in our study. Also, the possible maternal
imprinting effect on STOX1 is a matter of debate (Berends et al., 2007;
Iglesias-Platas et al., 2007; van Dijk et al., 2007). We are not able to
evaluate this in a case–control cohort, and epigenetic effects will
lessen our power to detect a true association. However, the strength
of this study is a large sample size, and the extensive clinical infor-
mation available.
In conclusion, we present novel observations suggesting involve-
ment of STOX2 in the pathogenesis of pre-eclampsia with FGR. We
conﬁrm Rigourd’s ﬁndings in decidual tissue, and link the transcrip-
tional alterations observed with STOX1A over expression to altera-
tions seen in deciduas of pre-eclamptic women delivering FGR
neonates. Conceivably, these ﬁndings might reﬂect a role for the
STOX genes in the pathophysiology of pre-eclampsia with FGR.
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